Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (49)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Kasahara, Y.
Right arrow Articles by Taniguchi, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kasahara, Y.
Right arrow Articles by Taniguchi, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol 10, 195-202, Copyright © 1998 by Oxford University Press


ARTICLES

Novel Fas (CD95/APO-1) mutations in infants with a lymphoproliferative disorder

Y Kasahara, T Wada, Y Niida, A Yachie, H Seki, Y Ishida, T Sakai, F Koizumi, S Koizumi, T Miyawaki and N Taniguchi
Department of Pediatrics, School of Medicine, Kanazawa University, Ishikawa, Japan.

Fas is an apoptosis-signaling receptor important for homeostasis of the immune system. In this study, Fas-mediated apoptosis and Fas mutations were analyzed in three Japanese children from two families with a lymphoproliferative disorder characterized by lymphadenopathy, hepatosplenomegaly, pancytopenia, hypergammaglobulinemia and an increase in TCR alphabeta+ CD4- CD8- T cells. Apoptosis induced by anti- Fas mAb was defective in both activated T cells and B cells, and granulocytes from these patients. Truncated Fas receptor lacking the cytoplasmic death domain caused by a point mutation in the splice region of intron 7 were demonstrated in two siblings. A homozygous point mutation in the splice acceptor of intron 3 was found in the Fas gene of the third patient, which resulted in the skipping of exon 4 and complete loss of Fas expression. Corresponding to these mutations, soluble Fas concentrations were decreased and reciprocally soluble Fas ligands were increased in patients' sera. Interestingly, co-stimulation by immobilized anti-Fas mAb in T cells from the two siblings was comparable to that seen in normal T cells. These results suggest that Fas-mediated apoptosis plays a pivotal role in immunological homeostasis in vivo, especially regarding clonal deletion of immune cells in humans.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BloodHome page
V. Mateo, M. Menager, G. de Saint-Basile, M.-C. Stolzenberg, B. Roquelaure, N. Andre, B. Florkin, F. le Deist, C. Picard, A. Fischer, et al.
Perforin-dependent apoptosis functionally compensates Fas deficiency in activation-induced cell death of human T lymphocytes
Blood, December 15, 2007; 110(13): 4285 - 4292.
[Abstract] [Full Text] [PDF]


Home page
NEJMHome page
E. Holzelova, C. Vonarbourg, M.-C. Stolzenberg, P. D. Arkwright, F. Selz, A.-M. Prieur, S. Blanche, J. Bartunkova, E. Vilmer, A. Fischer, et al.
Autoimmune Lymphoproliferative Syndrome with Somatic Fas Mutations
N. Engl. J. Med., September 30, 2004; 351(14): 1409 - 1418.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
F. Yanai, E. Ishii, K. Kojima, A. Hasegawa, T. Azuma, S. Hirose, N. Suga, A. Mitsudome, M. Zaitsu, Y. Ishida, et al.
Essential Roles of Perforin in Antigen-Specific Cytotoxicity Mediated by Human CD4+ T Lymphocytes: Analysis Using the Combination of Hereditary Perforin-Deficient Effector Cells and Fas-Deficient Target Cells
J. Immunol., February 15, 2003; 170(4): 2205 - 2213.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
M. Yasukawa, H. Ohminami, J. Arai, Y. Kasahara, Y. Ishida, and S. Fujita
Granule exocytosis, and not the Fas/Fas ligand system, is the main pathway of cytotoxicity mediated by alloantigen-specific CD4+ as well as CD8+ cytotoxic T lymphocytes in humans
Blood, April 1, 2000; 95(7): 2352 - 2355.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Rieux-Laucat, S. Blachere, S. Danielan, J. P. De Villartay, M. Oleastro, E. Solary, B. Bader-Meunier, P. Arkwright, C. Pondare, F. Bernaudin, et al.
Lymphoproliferative Syndrome With Autoimmunity: A Possible Genetic Basis for Dominant Expression of the Clinical Manifestations
Blood, October 15, 1999; 94(8): 2575 - 2582.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Jenkins, M. Keir, and J. M. McCune
Fas Is Expressed Early in Human Thymocyte Development But Does Not Transmit an Apoptotic Signal
J. Immunol., August 1, 1999; 163(3): 1195 - 1204.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Yasukawa, H. Ohminami, Y. Yakushijin, J. Arai, A. Hasegawa, Y. Ishida, and S. Fujita
Fas-Independent Cytotoxicity Mediated by Human CD4+ CTL Directed Against Herpes Simplex Virus-Infected Cells
J. Immunol., May 15, 1999; 162(10): 6100 - 6106.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
D. A. Martin, L. Zheng, R. M. Siegel, B. Huang, G. H. Fisher, J. Wang, C. E. Jackson, J. M. Puck, J. Dale, S. E. Straus, et al.
Defective CD95/APO-1/Fas signal complex formation in the human autoimmune lymphoproliferative syndrome, type Ia
PNAS, April 13, 1999; 96(8): 4552 - 4557.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
H. Ohminami, M. Yasukawa, S. Kaneko, Y. Yakushijin, Y. Abe, Y. Kasahara, Y. Ishida, and S. Fujita
Fas-Independent and Nonapoptotic Cytotoxicity Mediated by a Human CD4+ T-Cell Clone Directed Against an Acute Myelogenous Leukemia-Associated DEK-CAN Fusion Peptide
Blood, February 1, 1999; 93(3): 925 - 935.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.